BioSpace News Archive

Data offering provides significant coverage of chronic conditions, including immunology, cardiovascular, metabolic, neurology, respiratory and rare disease conditions

AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, today announced the completion of a Phase 1 clinical study in Indonesia of its personalized vaccine candidate, AV-COVID-19, for the novel coronavirus (SARS-CoV-2).

Medisafe announced that it has raised $30 million in Series C funding with investments led by Sanofi Ventures and ALIVE Israel HealthTech Fund, joined by Leumi Partners, Menorah Mivtachim and Consensus Business Group, previous investors Pitango Ventures, 7wireVentures, Merck Ventures, Octopus Ventures, lool HealthTech, Triventures and Ourcrowd.

Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that its chief executive officer, Doug Murphy-Chutorian , and chief marketing officer, Dennis Rosenberg , will present a company overview at the H. C, Wainwright Global Life Sciences Conference

Kindred Biosciences, Inc., a biopharmaceutical company focused on saving and improving the lives of pets, announced that it has submitted efficacy data to support the prophylactic indication for KIND-030 to the United States Department of Agriculture Center for Veterinary Biologics for review.

The new NKF Patient Network will help improve the lives of people with kidney disease through research, clinical care, drug development, and supportive health policy decisions

AdMeTech Foundation’s 12th Annual Prostate Cancer Awareness Day at the State House Highlights Massachusetts Model of National Leadership in Public Awareness, Medical Education and Research

Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year end financial results on Thursday, March 11, 2021

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced additional details on its webinar series examining major trends in the global infectious disease landscape.

PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) (TSXV: PSYB) (the “ Company ”) is pleased to announce that at the opening of the market today, the Company’s subordinate voting shares will commence trading on the TSX Venture Exchange (the “ TSXV ”) under the ticker symbol “PSYB”.